DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = APD334; Adalimumab; CICLOSPORIN; Canakinumab; Ciclosporin; Cosentyx; Cosentyx®; EU/1/14/980/002; EU/1/14/980/003; Gelatin; Gevokizumab; Gevokizumab open-label; Humira; IFX-1; Infliximab; Ixekizumab; Neoral Oral Solution; Neoral soft gelatin capsules; PREDNISOLONE; Prednisolone; Secukinumab; Secukinumab 150 mg (2 injections per dose; Stelara; USTEKINUMAB; Ustekinumab; Xilonix

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-002920-41-DE (EUCTR)	04/01/2012	24/08/2011	Stelara® (Ustekinumab) treatment in Patients with Pyoderma gangrenosum	Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients. - SPG-Trial	Patients with a clinical diagnosis of Pyoderma gangrenosum MedDRA version: 14.1;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Trade Name: Stelara Product Name: Ustekinumab Other descriptive name: USTEKINUMAB	University Hospital Tübingen	NULL	Not Recruiting			Female: yes Male: yes			Germany

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2011-002920-41-DE
(EUCTR)

04/01/2012

24/08/2011

Stelara® (Ustekinumab) treatment in Patients with Pyoderma gangrenosum

Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients. - SPG-Trial

Patients with a clinical diagnosis of Pyoderma gangrenosum
MedDRA version: 14.1;Level: LLT;Classification code 10037634;Term: Pyoderma gangenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

Trade Name: Stelara
Product Name: Ustekinumab
Other descriptive name: USTEKINUMAB

University Hospital Tübingen

NULL

Not Recruiting

Female: yes
Male: yes

Germany